Mkts

Vaxcyte, Inc.

NASDAQ: PCVX
$63.89+1.97 (+3.18%)
As of Nov 6, 4:00 PM ET

Key statistics

Day range
61.1465.30
52-week range
40.1490.75
Today
Open61.92
Previous close63.89
Volume—
Valuation
Market cap10.06B
P/E ratio—
EPS (TTM)-7.64
Income & risk
Dividend / yield—
Beta1.26
Avg volume1.83M
Discussion

PCVX News

Stories mentioning PCVX from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue
Cost of Goods Sold
Gross Profit0.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development312,779242,060209,933194,179148,134133,614116,936131,507
Sales General & Admin
Total Operating Expenses345,850274,283242,380226,219180,793162,169139,924152,981
Operating Income (Loss)(345,850)(274,283)(242,380)(226,219)(180,793)(162,169)(139,924)(152,981)
Interest Income26,61026,45129,25931,07332,93536,45828,05723,813
Interest Expense
Other Expense(1,382)1,325291.0028,5737,140(11,369)8,743465.00
Pretax Income
Tax Provision0.000.000.000.000.000.000.000.00
Net Income (Loss)(320,622)(246,507)(212,830)(166,573)(140,718)(137,080)(103,124)(128,703)
Earnings Per Share (Basic)(2.30)(1.81)(1.56)(1.22)(1.04)(1.12)(0.83)(1.10)
Earnings Per Share (Diluted)(2.30)(1.81)(1.56)(1.22)(1.04)(1.12)(0.83)(1.10)
Weighted Average Shares Outstanding (Basic)139,507136,090136,197136,034135,691121,997123,693117,257
Weighted Average Shares Outstanding (Diluted)139,507136,090136,197136,034135,691121,997123,693117,257

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About PCVX

Vaxcyte, Inc. (NASDAQ: PCVX) is a stock listed on the Nasdaq Stock Market under the ticker symbol PCVX. It last traded at $63.89 (Nov 6, 2026, 4:00 PM ET), up 3.2% on the day. That gives Vaxcyte a market capitalisation of $10.1B.

Over the past 52 weeks PCVX has traded between $40.14 and $90.75.

For the quarter ended Mar 31, 2026 it reported a net loss of $320.6M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026—-$320.6M
Dec 31, 2025—-$246.5M
Sep 30, 2025—-$212.8M
Jun 30, 2025—-$166.6M

From Vaxcyte’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…